Invited speakers

KLK Genetics and Genomics

George YOUSSEF (Toronto, Canada) : The non-coding genome: exploring a new dimension in Kallikrein research

Jyotsna BATRA (Brisbane, Australia): Kallikreins in post-GWAS era

Structural and functional aspects of Kallikreins

Peter GOETTIG (Salzburg, Austria): The regulatory loop network of the KLKs

Jonathan HARRIS (Brisbane, Australia): Perspectives on peptide-based kallikrein inhibition: Coup de foudre or coup de folie?

KLKs in malignant diseases

Judith CLEMENTS (Brisbane, Australia): KLK peptidases in the tumour microenvironment

Andreas SCORILAS (Athens, Greece): KLK gene targeted non-coding RNAs (ncRNAs) and novel KLK transcripts: A new generation of multifactorial tumor biomarkers

Viktor MAGDOLEN (Munich, Germany): The clinical relevance of kallikrein-related peptidases in ovarian cancer.

Hans LILJA (New York, USA): Translation of data from prostate cancer susceptible GEM expressing abundant levels of catalytic vs. non catalytic PSA specifically in their prostates to improve the specificity in screening for lethal prostate cancer at early stage.

KLKs in physiology and non-malignant diseases

François ALHENC-GELAS (Paris, France): Kallikrein (K1)-kinins-kininase (ACE) in cardiovascular and renal diseases; new therapeutic developments.

Isobel SCARISBRICK (Rochester, USA). Kallikreins as Signaling Molecules in the Central Nervous System.

KLKs in skin disorders

Radislav SEDLACEK (Prague, Czech Republic): A TALE of novel mouse models to study KLK-networks in vivo.

Oliver SCHILLING (Freiberg, Germany): Proteomic Approaches for a Better Understanding of Cellular Proteolysis.

KLKs in tissue and cell signaling

François MARCEAU (Québec, Canada): Tissue kallikrein (KLK-1) relationship with the bradykinin B1 and B2 receptors

Morley HOLLENBERG (Calgary, Canada): KLKs and microenvironment signaling in cancer and inflammation.

KLKs and immunity

Georgia SOTIROPOULOU (Patras, Greece): Update on KLKs and immunity

Carlos FIGUEROA (Valvidia, Chile):  Interrelationship between the kallikrein-related peptidases family and the classical kinin system in the human neutrophil.

Perspectives: Monoclonal antibodies to therapeutically target kallikreins

Anne POUPON (Tours, France): Bioinformatics methods for antibody development.

Emma LIAUDET (Montpellier, France): Targeting the protease cathepsin D in the tumor microenvironment of triple-negative breast cancer with human antibody.

John HOOPER (Brisbane, Australia): Inhibiting progression of ovarian cancer by antibody blockade of receptor activation mediated by kallikreins and other proteases.

David ULMERTH (Malmö, Sweden): Immune-targeting of uncomplexed PSA and hK2 for precision imaging and therapy.